
Opinion|Videos|August 1, 2024
IPF and PDE4B Inhibitors
Author(s)Steven D. Nathan, MD
Dr Nathan highlights the role of PDE4B inhibitors in IPF management.
Advertisement
Video content above is prompted by the following:
- What is the rationale for studying the phosphodiesterase 4 (PDE4) inhibitor pathway in idiopathic pulmonary fibrosis (IPF)?
- How do PDE4 inhibitors differ from PDE4B inhibitors?
- Why is this pathway of interest to pulmonologists and patients living with IPF?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5